Matsuda Masaru's most recent trade in Arcutis Biotherapeutics Inc was a trade of 6,330 Common Stock done at an average price of $14.3 . Disclosure was reported to the exchange on Aug. 4, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Arcutis Biotherapeutics Inc | Masaru Matsuda | See Remarks | Sale of securities on an exchange or to another person at price $ 14.33 per share. | 04 Aug 2025 | 6,330 | 197,364 (0%) | 0% | 14.3 | 90,687 | Common Stock |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | See Remarks | Sale of securities on an exchange or to another person at price $ 13.78 per share. | 28 May 2025 | 1,800 | 202,599 (0%) | 0% | 13.8 | 24,807 | Common Stock |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | See Remarks | Sale of securities on an exchange or to another person at price $ 15.20 per share. | 02 May 2025 | 5,030 | 204,399 (0%) | 0% | 15.2 | 76,453 | Common Stock |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 89,000 | 89,000 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 34,000 | 212,692 (0%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | See Remarks | Sale of securities on an exchange or to another person at price $ 13.03 per share. | 28 Feb 2025 | 3,263 | 209,429 (0%) | 0% | 13.0 | 42,520 | Common Stock |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | See Remarks | Sale of securities on an exchange or to another person at price $ 12.70 per share. | 03 Feb 2025 | 8,338 | 178,692 (0%) | 0% | 12.7 | 105,893 | Common Stock |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2024 | 4,875 | 183,148 (0%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | See Remarks | Sale of securities on an exchange or to another person at price $ 9.68 per share. | 18 Nov 2024 | 1,775 | 181,373 (0%) | 0% | 9.7 | 17,190 | Common Stock |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | See Remarks | Sale of securities on an exchange or to another person at price $ 8.68 per share. | 04 Nov 2024 | 5,015 | 178,273 (0%) | 0% | 8.7 | 43,551 | Common Stock |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | See Remarks | Sale of securities on an exchange or to another person at price $ 9.02 per share. | 02 Aug 2024 | 5,220 | 183,288 (0%) | 0% | 9.0 | 47,064 | Common Stock |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | See Remarks | Purchase of securities on an exchange or from another person at price $ 1.69 per share. | 31 May 2024 | 4,000 | 185,373 (0%) | 0% | 1.7 | 6,768 | Common Stock |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | See Remarks | Purchase of securities on an exchange or from another person at price $ 7.11 per share. | 31 May 2024 | 1,657 | 187,030 (0%) | 0% | 7.1 | 11,775 | Common Stock |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | See Remark | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2024 | 4,875 | 190,283 (0%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | See Remark | Sale of securities on an exchange or to another person at price $ 9.01 per share. | 27 May 2024 | 1,775 | 188,508 (0%) | 0% | 9.0 | 15,988 | Common Stock |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | See Remark | Sale of securities on an exchange or to another person at price $ 8.74 per share. | 02 May 2024 | 5,016 | 185,408 (0%) | 0% | 8.7 | 43,829 | Common Stock |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | See Remark | Sale of securities on an exchange or to another person at price $ 11.12 per share. | 04 Mar 2024 | 3,760 | 190,424 (0%) | 0% | 11.1 | 41,816 | Common Stock |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | See Remark | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2024 | 185,000 | 0 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | See Remark | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 74,000 | 148,634 (0%) | 0% | - | Common Stock | |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | See Remark | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2024 | 55,800 | 0 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | See Remark | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2024 | 35,300 | 0 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | See Remark | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 27,900 | 194,184 (0%) | 0% | - | Common Stock | |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | See Remark | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 17,650 | 166,284 (0%) | 0% | - | Common Stock | |
| Arcutis Biotherapeutics Inc | Matsuda Masaru | See Remark | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2024 | 176,000 | 176,000 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Matsuda Masaru | See Remark | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2024 | 28,000 | 74,634 (0%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 55,800 | 55,800 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 21,000 | 39,101 (0%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | See Remarks | Sale of securities on an exchange or to another person at price $ 15.82 per share. | 02 Mar 2023 | 1,416 | 18,119 (0%) | 0% | 15.8 | 22,398 | Common Stock |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | See Remarks | Sale of securities on an exchange or to another person at price $ 16.50 per share. | 02 Mar 2023 | 18 | 18,101 (0%) | 0% | 16.5 | 297 | Common Stock |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | See Remark | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2022 | 4,875 | 21,255 (0%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | See Remark | Sale of securities on an exchange or to another person at price $ 18.19 per share. | 18 Nov 2022 | 1,720 | 19,535 (0%) | 0% | 18.2 | 31,289 | Common Stock |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2022 | 4,875 | 18,175 (0%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 19.73 per share. | 27 May 2022 | 1,795 | 16,380 (0%) | 0% | 19.7 | 35,419 | Common Stock |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 35,300 | 35,300 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 13,300 | 13,300 (0%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 185,000 | 185,000 | - | - | Stock Option (Right to Buy) | |
| Halozyme Therapeutics Inc. | Masaru Matsuda | SVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Sep 2021 | 6,883 | 23,461 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | Masaru Matsuda | SVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Sep 2021 | 6,883 | 6,883 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | Masaru Matsuda | SVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.22 per share. | 04 Sep 2021 | 3,412 | 20,049 (0%) | 0% | 42.2 | 144,055 | Common Stock |
| Halozyme Therapeutics Inc. | Masaru Matsuda | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2021 | 23,311 | 23,311 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc. | Masaru Matsuda | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2021 | 13,544 | 13,544 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | Masaru Matsuda | SVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2021 | 6,257 | 18,769 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | Masaru Matsuda | SVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2021 | 6,257 | 17,699 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | Masaru Matsuda | SVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2021 | 4,129 | 8,258 | - | - | Restricted Stock | |
| Halozyme Therapeutics Inc. | Masaru Matsuda | SVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2021 | 4,129 | 18,625 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | Masaru Matsuda | SVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 50.60 per share. | 10 Feb 2021 | 3,203 | 14,496 (0%) | 0% | 50.6 | 162,072 | Common Stock |
| Halozyme Therapeutics Inc. | Masaru Matsuda | SVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 49.84 per share. | 10 Feb 2021 | 2,047 | 16,578 (0%) | 0% | 49.8 | 102,022 | Common Stock |
| Halozyme Therapeutics Inc. | Masaru Matsuda | SVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Sep 2020 | 6,884 | 13,766 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | Masaru Matsuda | SVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Sep 2020 | 6,884 | 13,822 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | Masaru Matsuda | SVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.70 per share. | 04 Sep 2020 | 2,380 | 11,442 (0%) | 0% | 27.7 | 65,926 | Common Stock |